The effect of n-3 polyunsaturated fatty acids on inflammation status in cancer patients: Updated systematic review and dose- and time-response meta-analysis

IF 2.4 Q3 NUTRITION & DIETETICS PharmaNutrition Pub Date : 2023-12-24 DOI:10.1016/j.phanu.2023.100372
Mehrdad Jamali , Meysam Zarezadeh , Parsa Jamilian , Zohreh Ghoreishi
{"title":"The effect of n-3 polyunsaturated fatty acids on inflammation status in cancer patients: Updated systematic review and dose- and time-response meta-analysis","authors":"Mehrdad Jamali ,&nbsp;Meysam Zarezadeh ,&nbsp;Parsa Jamilian ,&nbsp;Zohreh Ghoreishi","doi":"10.1016/j.phanu.2023.100372","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Reducing inflammation levels can potentially reduce treatment-induced complications in cancer patients. This meta-analysis aimed to determine the effect of n-3 PUFAs on three main biomarkers of inflammation: tumor necrosis factor-α(TNF-α), C-reactive protein (CRP), and interleukin-6 (IL-6).</p></div><div><h3>Methods</h3><p>A systematic search was conducted on PubMed, Scopus, and the Web of Science databases to find relevant studies. The difference between the intervention and control arms results was assessed by standardized mean differences (SMD) along with a 95% confidence interval.</p></div><div><h3>Result</h3><p>The study found that the SMD for TNF-α, CRP, and IL-6 was −0.63(95%CI:−0.89,−0.37, P &lt; 0.001), −0.27(95%CI:−0.64,0.10, P = 0.15), −0.59(95%CI:−0.89,−0.29, P &lt; 0.001) respectively, comparing the effects of n-3 PUFAs on study subjects compared to control. Subgroup analyses revealed heterogeneity sources for TNF-α and IL-6 but not for CRP. The study did not detect any indication of publication bias in the cases of TNF-α and CRP but detected it for IL-6.</p></div><div><h3>Conclusion</h3><p>N-3 PUFAs caused a significant reduction in levels of TNF-α IL-6 but not CRP in cancer patients. The findings support that n-3 PUFAs could be used as an add-on treatment for cancer patients, possibly because they reduce inflammation and do not have any known side effects in moderate doses.</p></div>","PeriodicalId":20049,"journal":{"name":"PharmaNutrition","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2023-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PharmaNutrition","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213434423000440","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Reducing inflammation levels can potentially reduce treatment-induced complications in cancer patients. This meta-analysis aimed to determine the effect of n-3 PUFAs on three main biomarkers of inflammation: tumor necrosis factor-α(TNF-α), C-reactive protein (CRP), and interleukin-6 (IL-6).

Methods

A systematic search was conducted on PubMed, Scopus, and the Web of Science databases to find relevant studies. The difference between the intervention and control arms results was assessed by standardized mean differences (SMD) along with a 95% confidence interval.

Result

The study found that the SMD for TNF-α, CRP, and IL-6 was −0.63(95%CI:−0.89,−0.37, P < 0.001), −0.27(95%CI:−0.64,0.10, P = 0.15), −0.59(95%CI:−0.89,−0.29, P < 0.001) respectively, comparing the effects of n-3 PUFAs on study subjects compared to control. Subgroup analyses revealed heterogeneity sources for TNF-α and IL-6 but not for CRP. The study did not detect any indication of publication bias in the cases of TNF-α and CRP but detected it for IL-6.

Conclusion

N-3 PUFAs caused a significant reduction in levels of TNF-α IL-6 but not CRP in cancer patients. The findings support that n-3 PUFAs could be used as an add-on treatment for cancer patients, possibly because they reduce inflammation and do not have any known side effects in moderate doses.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
n-3 多不饱和脂肪酸对癌症患者炎症状态的影响:最新系统综述及剂量和时间反应荟萃分析
背景降低炎症水平有可能减少癌症患者因治疗引起的并发症。这项荟萃分析旨在确定 n-3 PUFAs 对肿瘤坏死因子-α(TNF-α)、C 反应蛋白(CRP)和白细胞介素-6(IL-6)这三种主要炎症生物标志物的影响。方法在 PubMed、Scopus 和 Web of Science 数据库中进行系统搜索,以找到相关研究。结果研究发现,TNF-α、CRP和IL-6的SMD为-0.63(95%CI:-0.89,-0.37,P = 0.001)、-0.27(95%CI:-0.64,0.10,P = 0.15)、-0.59(95%CI:-0.89,-0.29,P = 0.001)。亚组分析显示,TNF-α和IL-6存在异质性,但CRP不存在异质性。结论n-3 PUFAs能显著降低癌症患者的TNF-α IL-6水平,但不能降低CRP水平。研究结果表明,n-3 PUFAs 可作为癌症患者的辅助治疗药物,这可能是因为适量的 n-3 PUFAs 可减轻炎症反应,而且没有任何已知的副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
PharmaNutrition
PharmaNutrition Agricultural and Biological Sciences-Food Science
CiteScore
5.70
自引率
3.10%
发文量
33
审稿时长
12 days
期刊最新文献
Advancements in psoriasis management: Integrating nutrient supplement with gut-brain-skin connection Can L-Methionine and S-Adenosyl-L-Methionine Effectively Mitigate Scopolamine-Induced Cognitive and Motor Deficits in Mice? Melatonin supplementation in preclinical colitis models: A systematic review and dose-response meta-analysis on inflammation, oxidative stress, and colon repair Efficacy and safety of liraglutide on C-reactive protein (CRP) in adults with type 2 diabetes: A GRADE-assessed systematic review and dose-response meta-analysis of controlled trials Editorial Board
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1